Received Feb 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 2 | xm42T | — |
patient received 2 doses of Arexvy; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 68-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number xm42T) for prophylaxis. Previously administered products included Arexvy (patient received 1st dose of Arexvy on 08th December, 2023 of batch number ar442). On 15-JAN-2025, the patient received the 2nd dose of Arexvy. On 15-JAN-2025, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: patient received 2 doses of Arexvy). The outcome of the extra dose administered was unknown. Additional Information: GSK receipt date: 16-JAN-2025 Other HCP reported that a male patient received the Arexvy shot on 08th December, 2023 and then received another dose on 15th January, 2025. Patient received 2 doses of Arexvy which led to extra dose administered. The vaccine administration facility was the same as primary reporter.